Welllll that doesn’t sound like a great idea

The two prospects:

Erutacidin, disrupts bacterial membranes through an uncommon interaction with the lipid cardiolipin and is effective against even the most challenging drug-resistant bacteria.

trigintamicin, acts on a protein-unfolding motor known as ClpX, a rare antibacterial target

The difficulty with bacterial DNA is that they have common elements and actively share DNA to boot. Sequencing only short sections make genome assembly unreliable. 200x longer sequences makes much more accurate genomes.

Then even if you find genes, we can't usually culture enough bacteria to make the product (typically instead injecting the sequences into bacteria we can culture). So being able to make the product without culturing the organism is key.